Clinical Trial

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients…

1 year ago

US AGRA JOINS ACANNABILITY AS A FOUNDING MEMBER

Partnering to pioneer standards within the field of novel cannabinoids CHICAGO, Dec. 3, 2024 /PRNewswire/ -- US Agra, a leading I.P.…

1 year ago

Biofrontera Inc. to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing…

1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each…

1 year ago

Dr. Alexander Taghva Introduces Focused Ultrasound Treatment for Essential Tremors in Orange County, CA

Focused Ultrasound Therapy for tremors is now available for patients with Dr. Taghva in Orange County MISSION VIEJO, CAPELLEN /…

1 year ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to…

1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…

1 year ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8…

1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024…

1 year ago